Helioxanthin

• Description:

  Helioxanthin (ACH126447) has in vitro antiviral activity with an EC50 of 1 μM against HBV and is also active against flaviviruses.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  HBV; HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/helioxanthin.html

• Purity:

  99.76

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1OCC2=C(C3=CC=C(OCO4)C4=C3)C5=C6OCOC6=CC=C5C=C21

• Molecular Formula:

  C20H12O6

• Molecular Weight:

  348.31

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Yeo H, et al. Synthesis and antiviral activity of helioxanthin analogues. J Med Chem. 2005 Jan 27;48 (2) :534-46.|[2]Cheng, Y. C.; Chou, C. K.; Fu, L.; Kuo, Y. H.; Yeh, S. F.; Zhu, J.; Zhu, Y. Inhibition and treatment of hepatitis B virus and flavivirus by helioxanthin and its analogues. U.S. Patent 6306899 B1, 2001.|[3]Ying C, et al. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother. 2010;21 (2) :97-103.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• CAS Number:

  [18920-47-3]